Clinical trial data of XP19986, XP13512 to be presented at Associated Professional Sleep Society meeting

XenoPort announced today that data from clinical trials of its product candidates arbaclofen placarbil and XP13512 (gabapentin enacarbil) will be presented at the Associated Professional Sleep Society meeting in San Antonio, Texas. The following data will be presented:

Arbaclofen placarbil, also known as XP19986
GERD

  • Arbaclofen Placarbil Improves Sleep Quality in Patients with Proton Pump Inhibitor (PPI) - Responsive Gastroesophageal Reflux Disease (GERD)
    Session: P15 Medical Disorders and Their Effects on Sleep: June 7, 2010, 10:30 a.m. - 12:30 p.m. CDT
    Poster #: 270

XP13512 (gabapentin enacarbil)
Moderate-to-Severe Primary Restless Legs Syndrome

  • A Randomized, Crossover Polysomnography Study of Gabapentin Enacarbil In Subjects with Moderate-to-Severe Primary Restless Legs Syndrome and Associated Sleep Disturbance
    Oral Session: O15: Treatment Advances in Restless Legs Syndrome: June 8, 2010, 2:15 p.m. - 2:30 p.m. CDT
  • Subjective Post-Sleep Diary Findings from a Polysomnography Study of Gabapentin Enacarbil in Subjects with Primary Restless Legs Syndrome and Associated Sleep Disturbance
    Session: P27 Pharmacologic Management of Restless Legs Syndrome: June 8, 2010, 10:15 a.m. - 12:15 p.m. CDT
    Poster #: 261
  • An Open-Label, 52-Week Extension Study Assessing Tolerability and Efficacy of Gabapentin Enacarbil in Subjects with Primary Restless Legs Syndrome
    Session: P27 Pharmacologic Management of Restless Legs Syndrome: June 8, 2010, 10:15 a.m. - 12:15 p.m. CDT
    Poster #: 262
  • Population Pharmacokinetic-Pharmacodynamic Relationship of Gabapentin after Administration of Gabapentin Enacarbil in Subjects with Restless Legs Syndrome
    Session: P27 Pharmacologic Management of Restless Legs Syndrome: June 8, 2010, 10:15 a.m. - 12:15 p.m. CDT
    Poster #: 263
  • Effects of Gabapentin Enacarbil on Quality of Life, Mood, and Function in Subjects with Restless Legs Syndrome (RLS)
    Session: P27 Pharmacologic Management of Restless Legs Syndrome: June 8, 2010, 10:15 a.m. - 12:15 p.m. CDT
    Poster #: 264
  • Gabapentin Enacarbil Maintains Improvements in Sleep During Long-term Treatment in Subjects with Moderate-to-Severe Primary Restless Legs Syndrome
    Session: P27 Pharmacologic Management of Restless Legs Syndrome: June 8, 2010, 10:15 a.m. - 12:15 p.m. CDT
    Poster #: 265
  • An Evaluation of Restless Legs Syndrome Symptom Augmentation in Subjects Treated with Gabapentin Enacarbil for 12 weeks: Secondary Integrated Analyses from Two Studies
    Session: P27 Pharmacologic Management of Restless Legs Syndrome: June 8, 2010, 10:15 a.m. - 12:15 p.m. CDT
    Poster #: 266
  • Gabapentin Enacarbil Relieves the Pain Associated with Restless Legs Syndrome (RLS)
    Session: P27 Pharmacologic Management of Restless Legs Syndrome: June 8, 2010, 10:15 a.m. - 12:15 p.m. CDT
    Poster #: 267
  • Gabapentin Enacarbil Improves Restless Legs Syndrome (RLS) Symptoms and Subjective Measures of Sleep in Subjects With Primary RLS With and Without Severe Sleep Disturbance: Secondary Analyses from Two Studies
    Session: P27 Pharmacologic Management of Restless Legs Syndrome: June 8, 2010, 10:15 a.m. - 12:15 p.m. CDT
    Poster #: 268
Source:

XenoPort, Inc.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
New study strengthens the link between sleep-disordered breathing and gestational diabetes